HERON THERAPEUTICS, INC. /DE/ (HRTX) Financial Forecast
United States · Health Care · USD (Thousands) · Annual
Key financials
USD|Thousands
ROE
209.08%
2025 (actual)
ROA
-8.26%
2025 (actual)
Gross Margin
73.31%
2025 (actual)
Net Margin
-13.04%
2025 (actual)
Total Assets
$255,877.00K
2025 (actual)
Net Income
-$20,195.00K
2025 (actual)
Valuation
$246,808.00K
2026 (forecast)
Stock Price
$1.30
Historical & projected performance
USD|Thousands
Reported figures and Equlion model projections for the next 5 years.
ROE
-163.4 pt
Company
Sector average
ROA
-0.7 pt
Company
Gross Margin
-16.8 pt
Company
Sector average
Net Margin
-6.4 pt
Company
Total Assets
+45.9%
Company
Sector average (own scale)
Net Income
-60.9%
Company
Valuation
+199.7%
Company
Sector average (own scale)
Stock Price
+200%
Company
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for HERON THERAPEUTICS, INC. /DE/? It covers the balance sheet, income statement, cash flow and Equlion model projections.